Quantcast
Last updated on April 17, 2014 at 14:35 EDT

Latest Clinical research Stories

2014-03-20 12:32:57

RALEIGH, N.C., March 20, 2014 /PRNewswire/ -- Clintrax Global, Inc., a worldwide clinical trial contract negotiation company located in Raleigh, NC, recently announced the addition of global investigator payments to its list of client services. Investigator payments are an essential part of the clinical trial lifecycle in which the site and other responsible contracting parties are compensated for services rendered and work performed throughout the course of a particular study....

2014-03-20 12:29:25

LONDON, March 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Liver Fibrosis Global Clinical Trials Review, H2, 2013 Liver Fibrosis Global Clinical Trials Review, H2, 2013SummaryGlobalData's clinical trial report, "Liver Fibrosis Global Clinical Trials Review, H2, 2013" provides data on the Liver Fibrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Liver Fibrosis. It includes an...

2014-03-20 08:30:21

Locating Investigational Sites Has Never Been Easy. COSTA MESA, Calif., March 20, 2014 /PRNewswire-iReach/ -- WCCT Global, a full service CRO specializing in early and late phase clinical research announced today the implementation of a cutting edge technology that allows WCCT Global to assist sponsors in identifying clinical investigational sites (CIS) that would be the best fit for their upcoming clinical trial anywhere in the United States. Clinical Investigational Sites are...

2014-03-19 23:25:02

EPI-743 gains key regulatory endorsement. Downingtown, PA, (PRWEB) March 19, 2014 Edison Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Status to EPI-743 for the treatment of Friedreich’s ataxia (http://www.prnewswire.com/news-releases/fda-awards-fast-track-status-to-edison-pharmaceuticals-epi-743-for-friedreichs-ataxia-250558901.html). This status will further accelerate the clinical development of EPI-743 now under way in two...

2014-03-19 23:24:32

General Genetics Corporation (GGC) announces a new pharmacogenomic testing study that investigates the frequency of adverse drug effects on a select population with known genetic variations that affect drug metabolic pathways, to determine if pharmacogenomic testing can ameliorate risks. Las Cruces, New Mexico (PRWEB) March 19, 2014 General Genetics Corporation (GGC) announced today an investigative study of pharmacogenomic testing (PGx) value when managing criteria-specific patients who...

2014-03-19 23:02:33

Pharmaceutical manufacturers are required by the FDA to train personnel in FDA quality system requirements and procedures. Now manufacturers can train their staff for significantly less money, in their own office, with a new training video developed by a former FDA investigator. Falls Church, VA (PRWEB) March 19, 2014 Quality Systems Training DVD for Drugmakers **FDAnews DVD Training Course** http://www.fdanews.com/QualityDrugDVD Pharmaceutical manufacturers are required by the FDA to...

2014-03-19 16:23:48

DUBLIN, March 19, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Noven Pharmaceuticals, Inc. to settle all outstanding patent litigation related to Actavis' generic version of Daytrana(® )(Methylphenidate Transdermal System). Daytrana(®) is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. Under the terms of the agreement, Noven will grant Actavis a non-exclusive, royalty-bearing...

2014-03-19 08:30:04

FDNA launches Face2Gene[TM], a search and reference mobile app powered by its proprietary Facial Dysmorphology Novel Analysis technology NEW YORK, March 19, 2014 /PRNewswire/ -- FDNA(R) (http://www.fdna.com) - a pioneer in computer-aided dysmorphology analysis has announced the availability of Face2Gene - a genetic search and reference mobile application powered by the Facial Dysmorphology Novel Analysis technology. Face2Gene facilitates detection of facial...

2014-03-19 08:29:30

BEIJING, March 19, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has received the Good Manufacturing Practice ("GMP") certification from China Food and Drug Administration ("CFDA") in respect of its plasma production facility at its Guizhou subsidiary. Mr. David (Xiaoying) Gao, Chairman and Chief Executive Officer of...

2014-03-19 08:28:22

Increases global capacity and adds new secondary packaging and labeling services to more efficiently deliver clinical trial supplies BOSTON, March 19, 2014 /PRNewswire/ -- PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the expansion of its global Clinical Logistics Services (CLS) capabilities. A new, state-of-the-art distribution center in Singapore and the recent expansion of the Company's facilities in...